ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc (CDT)

0.1015
0.00
(0.00%)
Closed November 13 4:00PM
0.00
0.00
(0.00%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.1015
Bid
0.1019
Ask
0.102
Volume
-
0.00 Day's Range 0.00
0.0789 52 Week Range 7.7509
Market Cap
Previous Close
0.1015
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
13,173,939
Shares Outstanding
96,004,699
Dividend Yield
-
PE Ratio
-267.04
Earnings Per Share (EPS)
-0.06
Revenue
-
Net Profit
-6.06M

About Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CDT. The last closing price for Conduit Pharmaceuticals was $0.10. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of $ 0.0789 to $ 7.7509.

Conduit Pharmaceuticals currently has 96,004,699 shares outstanding. The market capitalization of Conduit Pharmaceuticals is $9.74 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -267.04.

CDT Latest News

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a...

Conduit Pharmaceuticals to Join Russell 3000® Index

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market...

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), an internally managed, diversified real estate investment...

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its...

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge...

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0085-7.727272727270.110.1180.092177725770.10365464CS
40.00050.495049504950.1010.140.0789148226770.11456967CS
12-0.0576-36.2036455060.15910.1780.0789131739390.11589022CS
26-2.8685-96.58249158252.973.280.0789118423610.15391401CS
52-1.1385-91.8145161291.247.75090.078960365220.18601413CS
156-12.4985-99.194444444412.612.890.078953804790.21603898CS
260-12.4985-99.194444444412.612.890.078953804790.21603898CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 13.91
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 65.61
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.17
(0.00%)
0
AACGATA Creativity Global
$ 1.03
(0.00%)
0
AALAmerican Airlines Group Inc
$ 13.91
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 65.61
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.17
(0.00%)
0
AACGATA Creativity Global
$ 1.03
(0.00%)
0
AALAmerican Airlines Group Inc
$ 13.91
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 65.61
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.17
(0.00%)
0
AACGATA Creativity Global
$ 1.03
(0.00%)
0

Discussion

View Full Feed
No Posts Found

Your Recent History

Delayed Upgrade Clock